PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS: RUSSIAN AND INTERNATIONAL GUIDELINES by E. L. Nasonov

“…The lecture considers the present trends in the strategy of pharmacotherapy for rheumatoid  arthritis (RA) in the light of the guidelines by the European  League Against Rheumatism, the American College of Rheumatology and the All-Russian Public Organization  "The Association of Rheumatologists  of Russia". …”
Get full text

THE 2016 EULAR GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF EARLY ARTHRITIS by E. L. Nasonov

“…The article discusses new European League Against Rheumatism (EULAR) guidelines for the management of patients with early arthritis, which reflect the past decade's advances in new methods for the diagnosis and treatment of early arthritis primarily as a cardinal RA symptom complex. …”
Get full text

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS by E. L. Nasonov

“…This publication that is a continuation of a series of papers devoted to the discussion of the main points of the 2013 European League against Rheumatism (EULAR) guidelines for the treatment of early RA, deals with the place of GC. …”
Get full text

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS by E. L. Nasonov

“…This publication that is a continuation of a series of papers devoted to the discussion of the main points of the 2013 European League against Rheumatism (EULAR) guidelines for the treatment of early RA, deals with the place of GC. …”
Get full text

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS by E. L. Nasonov

“…This publication that is a continuation of a series of papers devoted to the discussion of the main points of the 2013 European League against Rheumatism (EULAR) guidelines for the treatment of early RA, deals with the place of GC. …”
Get full text

Irreversible organ damages in patients with systemic lupus erythematosus. SLICC damage index by E. S. Solovyeva, E. A. Aseeva, T. A. Lisitsyna, T. V. Popkova, S. K. Solovyev, E. L. Nasonov

“…According to the guidelines of the US Food and Drug Administration (FDA) and the European League Against Rheumatism (EULAR), DI along with activity indices (SLEDAI, BILAG) is indicated to be included in the comprehensive assessment of performed therapy in patients with SLE.…”
Get full text

The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part I by N. L. Kozlovskaya, S. K. Solovyev, E. A. Aseeva, T. V. Popkova, T. A. Panafidina, E. L. Nasonov, A. M. Lila, A. A. Mesnyankina, N. Yu. Nikishina

“…The paper presents the main provisions of the 2019 updated European League Against Rheumatism (EULAR)/European Renal Association (ERA) – European Dialysis and Transplant Association (EDTA) guidelines for the management of lupus nephritis. …”
Get full text

Risk factors for venous thromboembolic events in patients with rheumatoid arthritis by M. A. Satybaldyeva, T. M. Reshetnyak, N. V. Seredavkina, S. I. Glukhova, D. E. Karateev, E. L. Nasonov

“…The investigation enrolled 362 patients (302 women and 60 men) with RA fulfilling the 2010 American College of Rheumatology/European League Against Rheumatism criteria. The patients' mean age was 53.7±13.3 years; the disease duration was 12.4±10.9 years. …”
Get full text

CLINICAL CHARACTERISTICS OF THREE COHORTS OF PATIENTS WITH EARLY- AND LATE-ONSET RHEUMATOID ARTHRITIS (AT 50 YEARS OR OLDER). GENERALIZATION OF 40 YEARS’ EXPERIENCE by A. M. Satybaldyev, N. V. Demidova, G. I. Gridneva, N. Yu. Nikishina, E. V. Gerasimova, D. A. Gukasian, K. A. Kasumova, E. L. Luchikhina, A. S. Misiyuk, T. G. Oskilko, O. A. Rumyantseva, E. A. Zlepko, L. N. Tyurina, E. V. Fedorenko, N. V. Shornikova, E. L. Nasonov

“…To establish its diagnosis, the investigators used classification criteria for each cohort of its period: 1) the 1958 American Rheumatism Association (ARA) criteria; 2) the 1987 ARA criteria, and 3) the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria. Along with a change in the criteria, diagnostic methods were improved in this period. …”
Get full text

Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice by D. A. Kusevich, A. S. Avdeeva, V. V. Rybakova, N. V. Chichasova, E. L. Nasonov

“…Examinations were made in 20 active seropositive RA patients who had not been previously treated with biological agents (BAs), but received two infusions of the rituximab biosimilar Acellbia® at a dose of 600 mg intravenously at a 2-week interval during stable therapy with methotrexate (MT) and glucocorticoids (GCs). The European League Against Rheumatism (EULAR) response criteria (Disease Activity Score 28 (DAS28), Clinical Disease Activity Index (CDAI), and Simplified Disease Activity Index) and the American College of Rheumatology (ACR) criteria were used to evaluate the efficiency of Acellbia® therapy. …”
Get full text

CHANGES IN CALPROTECTIN LEVEL, ITS RELATIONSHIP TO THE CLINICAL AND LABORATORY PARAMETERS OF DISEASE ACTIVITY AND SIGNIFICANCE FOR PREDICTING THE THERAPEUTIC RESPONSE IN RHEUMATOID... by A. O. Pchelintseva, A. P. Zhornyak, N. G. Ionichenok, E. Yu. Panasyuk, A. E. Ilyina, I. A. Andrianova, E. E. Gubar, E. S. Tsvetkova, M. V. Cherkasova, E. N. Aleksandrova, L. N. Denisov, E. L. Nasonov

“…Treatment efficacy was assessed according to the European League against Rheumatism (EULAR) criteria and the American College of Rheumatology (ACR) criteria. …”
Get full text

TIME COURSE OF CHANGES IN BLOOD LIPID PARAMETERS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS DURING TREAT-TO-TARGET ANTIRHEUMATIC THERAPY: ACCORDING TO 18-MONTH FOLLOW-UP FINDINGS by E. V. Udachkina, D. S. Novikova, T. V. Popkova, I. G. Kirillova, Yu. N. Gorbunova, E. I. Markelova, D. E. Karateev, E. L. Luchikhina, A. A. Novikov, E. N. Aleksandrova, N. V. Demidova, M. A. Kanonirova, G. V. Lukina, A. V. Volkov, E. L. Nasonov

“…Seventy-four patients (73% women; median age, 56 years) with early RA meeting the respective 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria and moderate or high activity (median DAS28-ESR score of 5.4) were examined within the framework of the REMARCA trial. …”
Get full text

ASSOCIATION BETWEEN ULTRASOUND SIGNS OF JOINT INFLAMMATION AND RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS by O. G. Alekseeva, M. V. Severinova, A. V. Smirnov, N. V. Demidova, E. N. Aleksandrova, A. A. Novikov, E. L. Luchikhina, D. E. Karateev, S. I. Glukhova, A. V. Volkov, E. L. Nasonov

“…Efficacy was assessed using the European League Against Rheumatism (EULAR) criteria, CDAI, and SDAI. …”
Get full text

ASSOCIATION BETWEEN CLINICAL MANIFESTATIONS AND ULTRASONIC SIGNS OF INFLAMMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS by O. G. Alekseeva, M. V. Severinova, N. V. Demidova, E. N. Aleksandrova, A. A. Novikov, E. L. Luchikhina, D. E. Karateev, A. V. Volkov, E. L. Nasonov

“…Therapeutic efficacy was evaluated using the European League Against Rheumatism (EULAR) criteria and activity indices (DAS28, CDAI, and SDAI). …”
Get full text